Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Sep 12, 2012 8:47am
405 Views
Post# 20351120

RE: Patents.

RE: Patents.

I guess spending all the R&D has helped build the patent portfolio. What strikes me though, and this is in reference to an old post I made, is that some of these patents are incredibly broad. One has to wonder if HEM's consultants may recommend a licensing strategy, which may or may not include litigation against firms that are infringing on HEM's patents. Now it's obvious that HEM simply doesn't have the resources on its own to pursue any legal action to enforce its patent rights, however a sale of patents to a patent house (e.g. something along the lines of how wi-lan works) could result in upfront proceeds and then that houses ability to conduct several lawsuits with a view to gaining royalties.

 

Months ago I would have thought that this strategy would never fly with management. Today, it's a whole new ballgame. I'm not suggesting this is what's going to happen, but would be an interesting scenario for the board/management to consider IF the patents could result in material royalty streams.

Bullboard Posts